PDF下载 ( 1475 KB)
Clinical effect of Kezhi capsules in treatment of nonalcoholic steatohepatitis
-
摘要:
目的观察壳脂胶囊对非酒精性脂肪性肝炎的临床疗效及安全性。方法选取2013年11月-2015年12月于上海市第八人民医院就诊的非酒精性脂肪性肝炎（NASH）患者100例,随机分为治疗组、对照组各50例,分别予壳脂胶囊和多烯磷脂酰胆碱胶囊,疗程24周。观察两组治疗前后肝功能、血脂水平及肝/脾CT值的变化。计量资料组间比较采用两独立样本的t检验,组内比较采用配对样本t检验,计数资料组间比较采用χ2检验。结果两组患者治疗后AST[（49.2±21.7）U/L vs（119.5±44.2）U/L,t=10.0,P<0.01;（52.4±33.1）U/L vs（115.2±48.3）U/L,t=7.6,P<0.01]、ALT[（41.8±14.8）U/L vs（92.8±42.1）U/L,t=8.1,P<0.01;（42.9±16.6）U/L vs（95.3±40.4）U/L,t=8.5,P<0.01]、GGT[（52.3±23.7）U/L vs（168.4±85.9）U/L,t=9.2,P<0.01;（54.8±30.2）U/L vs（177.6±88.7）U/L,...
Abstract:Objective To investigate the clinical effect and safety of Kezhi capsules in the treatment of nonalcoholic steatohepatitis( NASH). Methods A total of 100 patients with NASH who visited The Eighth People's Hospital of Shanghai from November 2013 to December 2015 were enrolled and randomly divided into treatment group and control group,with 50 patients in each group. The patients in the treatment group were treated with Kezhi capsules and those in the control group were treated with polyene phosphatidylcholine capsules. The course of treatment was 24 weeks for each group. The changes in liver function,blood lipid,and liver / spleen CT ratio after treatment were observed in both groups. The two- independent- samples t test was used for comparison of continuous data between groups,and the paired- samples t test was used for comparison of continuous data within each group. The chi- square test was used for comparison of categorical data between groups. Results After treatment,the treatment group and the control group had significant improvements in the levels of aspartate aminotransferase( 49. 2 ± 21. 7 U / L vs 119. 5 ± 44. 2 U / L,t = 10. 0,P < 0. 01; 52. 4 ± 33. 1 U / L vs 115. 2 ± 48. 3 U / L,t = 7. 6,P < 0. 01),alanine aminotransferase( 41. 8 ± 14. 8 U / L vs 92. 8 ± 42. 1 U / L,t = 8. 1,P < 0. 01; 42. 9 ± 16. 6 U / L vs 95. 3 ± 40. 4 U / L,t = 8. 5,P < 0. 01),gamma- glutamyl transpeptidase( 52. 3 ± 23. 7 U / L vs 168. 4 ± 85. 9 U / L,t = 9. 2,P < 0. 01; 54. 8 ± 30. 2 U / L vs177. 6 ± 88. 7 U / L,t = 9. 3,P < 0. 01),triglyceride( TG)( 1. 78 ± 1. 01 mmol / L vs 3. 52 ± 2. 35 mmol / L,t = 4. 8,P < 0. 01; 2. 51 ±1. 08 mmol / L vs 3. 65 ± 2. 43 mmol / L,t = 3. 0,P = 0. 02),total cholesterol( TC)( 3. 81 ± 1. 28 mmol / L vs 6. 13 ± 5. 22 mmol / L,t =3. 0,P = 0. 02; 3. 63 ± 1. 39 mmol / L vs 5. 27 ± 4. 54 mmol / L,t = 2. 6,P = 0. 03),and liver / spleen CT ratio( 0. 94 ± 0. 16 vs 0. 74 ±0. 18,t = 5. 8,P < 0. 01; 0. 89 ± 0. 13 vs 0. 70 ± 0. 20,t = 5. 6,P < 0. 01). There were significant differences in these parameters between the two groups. At the end of treatment,the treatment group had significantly greater reductions in TC and TG levels than the control group( t = 3. 5 and 2. 8,both P < 0. 01). Conclusion Kezhi capsules can effectively improve liver function,reduce blood lipids,and reduce the degree of fatty degeneration of the liver,without significant toxic and side effects.
-
Key words:
- fatty liver /
- Kezhi capusule /
- polyene phosphatidylcholine capusule /
- treatment outcome
-
[1]FANELL CC,LATER CZ.Nonaleoholie fatty liver disease:from steatosis to cirrhosis[J].Hepatology,2006,43(2):99-112. [2]de ALWIS NM,DAY CP.NON-aleoholic fatty liver disease:the mist gradua Jly clears[J].J Hepatol,2008,48(Suppl 1):104-112. [3]Review Team,LABRECQUE DR,ABBAS Z,et al.World Gastroenterolopy Organiastion Global Guidelines:nonalcoholic fatty liver disease and nonalcoholic steatohepatitis[J].J Clin Gastroenterol,2014,48(6):467-473. [4]SCHERER A,DUFOUR JF.Treatment of non alcoholic fatty liver disease[J].Dig Dis,2016,34(Suppl 1):27-31. [5]The Chinese National Workshop on Fatty Liver and Alcoholic,Liver disease for the Chinese Liver Disease Association.Guidelines for the diagnosis and treatment of nonalcoholic fatty liver disease[J].J Clin Hepatol,2010,26(2):120-124.(in Chinese)中华医学会肝病学分会脂肪肝和酒精性肝病学组.非酒精性脂肪性肝病诊疗指南[J].临床肝胆病杂志,2010,26(2):120-124. [6]ROMBOMS K,MARRA F.Molecular mechanisms of hepatic fibrosis in non-alcoholic steatohepatitis[J].Dig Dis,2010,28(1):229-235. [7]KUKLA M,CIUPINSKA-KAJOR M,KAJOR M,et al.Liver visfatin expression in morbidly obese patients with nonalcoholic fatty liver disease undrgoing bariatric surgery[J].Pol J Pathol,2010,61(3):147-153. [8]PAIS R,BARRITT AS,CALMUS Y,et al.NAFLD and liver transplantation:current burden and expected challenges[J].J Hepatol,2016,65(6):1245-1257. [9]DRAPKINA OM,DEEVA TA,VOLKOVA NP,et al.Current approaches to diagnosing and treating nonalcoholic fatty liver disease[J].Ter Arkh,2014,86(10):116-123. [10]MA JM,WANG JQ.Treatment of non-alcoholic fatty liver disease from deficiency[J].J Changchun Univ Tradit Chin Med,2014,30(5):850-852.(in Chinese)马菁蔓,王景朱.从虚论治非酒精性脂肪肝[J].长春中医药大学学报,2014,30(5):850-852. [11]WANG RB.Traditional Chinese medicine treatment of liver diseases[J].J Clin Hepatol,2015,31(1):2-6.(in Chinese)王融冰.肝病的中医药治疗[J].临床肝胆病杂志,2015,31(1):2-6. [12]ZHANG Y,XU SH.Pathogenic mechanism associated with insulin resistance and adiponectin abnormality in carotid atherosclerosis patients complicated with nonalcoholic fatty liver disease and their relationships with traditional Chinese medical syndrome types[J].J Guangzhou Univ Tradit Chin Med,2009,26(5):499-504.(in Chinese)张毅,徐尚华.颈动脉粥样硬化与非酒精性脂肪肝的胰岛素抵抗、脂联素异常相关机制及与中医证型关系分析[J].广州中医药大学学报,2009,26(5):499-504. [13]YANG YW,XIAO GM,ZHAO BM,et al.Randomized study of kezhi capsules in treating non-alcoholic fatty liver[J].The J Pract Med,2014,30(4):638-640.(in Chinese)杨跃武,肖阁敏,招柏明,等.壳脂胶囊治疗非酒精性脂肪肝的随机对照研究[J].实用医学杂志,2014,30(4):638-640. [14]WANG RQ,NAN YM,ZHAO SX,et al.Effects of Kezhi capsule on oxidative stress in mice with non-alcoholic steatohepatitis[J].Chin Hepatol,2011,16(3):216-219.(in Chinese)王荣琦,南月敏,赵素贤,等.壳脂胶囊对小鼠非酒精性脂肪性肝炎氧化应激的影响[J].肝脏,2011,16(3):216-219. [15]ZHAO WH,YU YQ,LIU LJ,et al.Experimental study of Kezhi capsule on PPAR-γand IR expression in non-alcoholic steatohepatitis rats[J].Chin J Integr Trad West Med Dig,2014,22(9):8-10.(in Chinese)赵唯含,余轶群,刘丽娟,等.壳脂胶囊对非酒精性脂肪性肝炎大鼠肝组织PPAR-γ、IR的作用研究[J].中国中西医结合消化杂志,2014,22(9):8-10. -
下载:
